MEDIA CONTACT
Available for logged-in reporters only
Newswise — HOUSTON ― The University of Texas MD Anderson Cancer Center today announced a strategic research collaboration with Denali Therapeutics Inc. to develop novel therapies for Alzheimer’s and other neurodegenerative diseases. Through this agreement, Denali will collaborate with researchers in the Neurodegeneration Consortium (NDC) at MD Anderson to investigate four therapeutic targets, with the goal of advancing novel small-molecule product candidates into clinical testing.
Neurodegenerative diseases, which affect millions of Americans, comprise a range of indications marked by deterioration of neurons in the human brain, explained Jim Ray, Ph.D., director of the NDC.
“Our team at the Neurodegeneration Consortium is committed to…
